Sartorius Group 2019 Annual Report 9

Sartorius Group 2019 Annual Report

9

Order Intake and Sales Revenue ? in millions

1,172.7 1,334.7 1,501.4 1,662.5 1,939.5 1,114.8 1,300.3 1,404.6 1,566.0 1,827.0

2,000

1,700

1,400

1,100

800 2015

Order intake Sales revenue

2016

2017

2018

2019

Underlying EBITDA and Margin1)

263.2 23.6

500

325.4 25.0

353.2 25.1

405.0 25.9

495.8 27.1

30

375

27

250

24

125

21

0 2015 2016 2017 2018

Underlying EBITDA in millions of ? Underlying EBITDA margin in %

18 2019

Key Figures

All figures are given in millions of ? according to the IFRS, unless otherwise specified Order intake, sales revenue and earnings Order intake Sales revenue Underlying EBITDA1) Underlying EBITDA1) as a % of sales revenue Relevant net profit2) Research and development costs

2019

2018

2017

2016

2015

1,939.5 1,827.0

495.8 27.1

209.3 95.6

1,662.5 1,566.0

405.0 25.9

175.6 78.2

1,501.4 1,404.6

353.2 25.1

144.0 68.8

1,334.7 1,300.3

325.4 25.0

132.6 59.4

1,172.7 1,114.8

263.2 23.6

107.4 52.5

Financial data per share3) Earnings per share2)

per ordinary share (in ?) per preference share (in ?) Dividende per ordinary share (in ?) per preference share (in ?)

3.06

2.56

2.10

1.93

1.59

3.07

2.57

2.11

1.94

1.60

0.704)

0.61

0.50

0.45

0.37

0.714)

0.62

0.51

0.46

0.38

Balance sheet Balance sheet total Equity Equity ratio (in %)

2,844.3 1,081.2

38.0

2,526.9 973.4 38.5

2,297.7 806.6 35.1

1,753.0 736.8 42.0

1,437.2 644.8 44.9

Financials Capital expenditures5) Capital expenditures as a % of sales5) Depreciation and amortization Cash from operating activities Net debt Gearing (underlying)

225.6 12.3

132.6 377.2 1,011.3

2.0

237.8 15.2

113.4 244.5 959.5

2.4

209.4 14.9 98.3

206.5 895.5

2.5

152.1 11.7 75.7

170.4 485.9

1.5

113.1 10.1 58.9

124.4 344.0

1.3

Total number of employees as of December 31

9,016

8,125

7,501

6,911

6,185

1) Underlying = excluding extraordinary items 2) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial

result, including the corresponding tax effects for each of these items 3) 2015 adjusted for stock split; rounded values 4) Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG 5) Since 2019 and as a result of the change in IFRS 16 accounting principles, CAPEX has been based on cash flow instead of balance sheet

computation; CAPEX restated for 2018: ?233.2 million; CAPEX ratio restated for 2018: 14.9%

Mission & Vision

Mission We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

Vision As pioneers, we are a magnet and a dynamic platform for the leading experts in our field. We bring creative minds together for a common goal: technological breakthroughs that lead to better health for more people.

An Overview of Our Divisions

As a leading international partner of biopharmaceutical research and the industry, Sartorius supports its customers in the development and manufacture of biotech medications and vaccines. Our goal is to make complex and expensive development of biopharmaceuticals and their production safer and more efficient. We cover the entire value-added chain of the biopharmaceutical industry and help with our products and services to ensure that novel therapies reach the market faster and are accessible to more people worldwide. Sartorius employs over 9,000 people across the globe and has Group companies in more than 30 countries.

Bioprocess Solutions

In the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company has held leading market positions for years in its core technologies, such as filtration, fermentation, cell cultivation and single-use bags and containers.

Key Figures

? in millions

2019

Sales revenue

1,372.1

Order intake

1,479.3

Underlying EBITDA

406.8

? As a % of sales

29.6

Employees as of Dec. 31 6,106

1) In constant currencies

2018 1,143.1 1,233.7

326.9 28.6

5,498

in % 18.1 1) 18.0 1) 24.5

11.1

Lab Products & Services

The Lab Products & Services Division offers laboratories in the pharmaceutical and biopharmaceutical industries as well as at academic research institutes innovative solutions for bioanalytics, in addition to premium laboratory products, consumables and services. Sartorius is among the market leaders in laboratory balances, pipettes and lab consumables.

Key Figures

? in millions Sales revenue Order intake Underlying EBITDA ? As a % of sales Employees as of Dec. 31

1) In constant currencies

2019 454.9 460.3

89.0 19.6 2,910

2018 423.0 428.8

78.1 18.5 2,627

in % 5.91) 5.71)

14.0

10.8

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download